The abnormal expression of the c-Met tyrosine kinase
has been linked
to the proliferation of several human cancer cell lines, including
non-small-cell lung cancer (NSCLC). In this context, the identification
of new c-Met inhibitors based on heterocyclic small molecules could
pave the way for the development of a new cancer therapeutic pathway.
Using multiple linear regression (MLR)-quantitative structure–activity
relationship (QSAR) and artificial neural network (ANN)-QSAR modeling
techniques, we look at the quantitative relationship between the biological
inhibitory activity of 40 small molecules derived from cyclohexane-1,3-dione
and their topological, physicochemical, and electronic properties
against NSCLC cells. In this regard, screening methods based on QSAR
modeling with density-functional theory (DFT) computations, in silico
pharmacokinetic/pharmacodynamic (ADME-Tox) modeling, and molecular
docking with molecular electrostatic potential (MEP) and molecular
mechanics-generalized Born surface area (MM-GBSA) computations were
used. Using physicochemical (stretch–bend, hydrogen bond acceptor,
Connolly molecular area, polar surface area, total connectivity) and
electronic (total energy, highest occupied molecular orbital (HOMO)
and lowest unoccupied molecular orbital (LUMO) energy levels) molecular
descriptors, compound 6d is identified as the optimal
scaffold for drug design based on in silico screening tests. The computer-aided
modeling developed in this study allowed us to design, optimize, and
screen a new class of 36 small molecules based on cyclohexane-1,3-dione
as potential c-Met inhibitors against NSCLC cell growth. The in silico
rational drug design approach used in this study led to the identification
of nine lead compounds for NSCLC therapy via c-Met protein targeting.
Finally, the findings are validated using a 100 ns series of molecular
dynamics simulations in an aqueous environment on c-Met free and complexed
with samples of the proposed lead compounds and Foretinib drug.